Keros Therapeutics (NASDAQ:KROS) Trading Up 10.8% - Still a Buy?

Key Points

• Keros Therapeutics stock rose 10.8% on Monday, reaching a trading high of $15.25 and closing at $15.33, with trading volume increasing by 74% from the average.
• Wells Fargo has initiated coverage with an "overweight" rating and a target price of $26, while the average target price from analysts is $30, indicating optimistic growth prospects.
• Major shareholders recently sold significant amounts of stock, with Pontifax Management 4 G.P. selling 4.8 million shares and Adar1 Capital Management offloading over 5.3 million shares, suggesting notable shifts in ownership.

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) rose 10.8% on Monday . The company traded as high as $15.25 and last traded at $15.33. Approximately 1,574,741 shares traded hands during mid-day trading, an increase of 74% from the average daily volume of 905,847 shares. The stock had previously closed at $13.83.

Analysts Set New Price Targets

KROS has been the subject of a number of research analyst reports. Wells Fargo & Company initiated coverage on shares of Keros Therapeutics in a research note on Monday. They issued an "overweight" rating and a $26.00 target price for the company. Weiss Ratings restated a "sell (d)" rating on shares of Keros Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright decreased their price objective on shares of Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating for the company in a report on Friday, August 8th. Seven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Keros Therapeutics currently has a consensus rating of "Hold" and an average target price of $30.00.

Keros Therapeutics Stock Up 9.8%

The company's fifty day moving average is $15.28 and its 200 day moving average is $14.28. The firm has a market cap of $617.02 million, a price-to-earnings ratio of 49.00, a PEG ratio of 1.78 and a beta of 0.97.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.38. Keros Therapeutics had a net margin of 8.06% and a return on equity of 2.96%. The business had revenue of $0.02 million during the quarter, compared to analysts' expectations of $3.83 million. During the same quarter in the prior year, the company posted ($1.25) earnings per share. The firm's revenue was up 49002.7% on a year-over-year basis. On average, equities research analysts forecast that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Insider Activity

In related news, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the company's stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total value of $84,975,125.25. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the firm's stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $95,659,436.00. The disclosure for this sale can be found here. 22.90% of the stock is owned by corporate insiders.

Institutional Trading of Keros Therapeutics

Several hedge funds have recently modified their holdings of the stock. CWM LLC increased its stake in Keros Therapeutics by 10,157.7% during the 1st quarter. CWM LLC now owns 2,667 shares of the company's stock valued at $27,000 after purchasing an additional 2,641 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in Keros Therapeutics by 149.2% during the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company's stock valued at $42,000 after purchasing an additional 1,888 shares during the last quarter. Farther Finance Advisors LLC purchased a new stake in Keros Therapeutics during the third quarter valued at about $47,000. Police & Firemen s Retirement System of New Jersey lifted its holdings in Keros Therapeutics by 29.7% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company's stock valued at $110,000 after purchasing an additional 1,892 shares during the last quarter. Finally, Entropy Technologies LP bought a new stake in shares of Keros Therapeutics during the first quarter valued at about $121,000. Institutional investors own 71.56% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.